Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 6,190 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly conducts its businesses within domestic and overseas markets.
01801.HK stock price ended at $83.2 on 火曜日, after dropping 2.52%
On the latest trading day Jan 20, 2026, the stock price of 01801.HK fell by 2.52%, dropping from $85.10 to $83.20. During the session, the stock saw a volatility of 3.99%, with prices oscillating between a daily low of $82.75 and a high of $86.05. On the latest trading day, the trading volume for 01801.HK decreased by 5.1M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 9.1M shares were traded, with a market value of approximately $143.1B.